From Wikipedia, the free encyclopedia
Chemical compound
Pimodivir
Trade names Pimodivir
Legal status
(2S ,3S )-3-[[5-fluoro-2-(5-fluoro-1H -pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]bicyclo[2.2.2]octane-2-carboxylic acid
CAS Number
PubChem
CID
UNII
Formula C 20 H 19 F 2 N 5 O 2
Molar mass 399.402 g·mol−1 3D model (
JSmol )
O=C(O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(-c2c[nH]c3ncc(F)cc23)ncc1F
InChI=1S/C20H19F2N5O2/c21-11-5-12-13(7-24-17(12)23-6-11)18-25-8-14(22)19(27-18)26-16-10-3-1-9(2-4-10)15(16)20(28)29/h5-10,15-16H,1-4H2,(H,23,24)(H,28,29)(H,25,26,27)/t9?,10?,15-,16-/m0/s1
Key:JGPXDNKSIXAZEQ-SBBZOCNPSA-N
Pimodivir (VX-787 , JNJ-63623872 ) is an
antiviral drug which was developed as a treatment for
influenza . It acts as an inhibitor of influenza virus polymerase basic protein 2, and has shown promising results in Phase II
clinical trials .
[1]
[2]
[3] However, in late 2021,
Janssen announced that the clinical development of pimidivir had been halted due to lack of benefit over standard of care.
[4]
See also
References
^ Trevejo JM, Asmal M, Vingerhoets J, Polo R, Robertson S, Jiang Y, et al. (2018). "Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: a Phase IIa, randomized, double-blind, placebo-controlled study". Antiviral Therapy . 23 (4): 335–344.
doi :
10.3851/IMP3212 .
PMID
29244026 .
S2CID
4005581 .
^ Finberg RW, Lanno R, Anderson D, Fleischhackl R, van Duijnhoven W, Kauffman RS, et al. (March 2019).
"Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial" . The Journal of Infectious Diseases . 219 (7): 1026–1034.
doi :
10.1093/infdis/jiy547 .
PMID
30428049 .
^ Beigel JH, Nam HH, Adams PL, Krafft A, Ince WL, El-Kamary SS, Sims AC (July 2019).
"Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference" . Antiviral Research . 167 : 45–67.
doi :
10.1016/j.antiviral.2019.04.006 .
PMC
7132446 .
PMID
30974127 .
^
"Janssen's lead coronavirus vaccine shows preclinical promise" . 4 September 2020.